uniQure/$QURE
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About uniQure
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases. Its program and pipeline involves: Huntington's Disease, Temporal Lobe Epilepsy (TLE), Fabry Disease, ALS (SOD1), Hemophilia B, Clinical Trials, and Research Programs.
Ticker
$QURE
Sector
Primary listing
Employees
221
Headquarters
Website
uniQure Metrics
BasicAdvanced
$1B
-
-$3.46
0.77
-
Price and volume
Market cap
$1B
Beta
0.77
52-week high
$71.50
52-week low
$7.76
Average daily volume
4.8M
Financial strength
Current ratio
10.426
Quick ratio
9.988
Long term debt to equity
267.837
Total debt to equity
269.778
Interest coverage (TTM)
-2.89%
Profitability
EBITDA (TTM)
-170.59
Gross margin (TTM)
-745.52%
Net profit margin (TTM)
-1,236.00%
Operating margin (TTM)
-1,151.38%
Effective tax rate (TTM)
-2.91%
Revenue per employee (TTM)
$70,000
Management effectiveness
Return on assets (TTM)
-16.77%
Return on equity (TTM)
-207.10%
Valuation
Price to revenue (TTM)
57.474
Price to book
5.04
Price to tangible book (TTM)
9.95
Price to free cash flow (TTM)
-5.186
Free cash flow yield (TTM)
-19.28%
Free cash flow per share (TTM)
-3.103
Growth
Revenue change (TTM)
-40.64%
Earnings per share change (TTM)
-29.73%
3-year revenue growth (CAGR)
-46.73%
10-year revenue growth (CAGR)
4.29%
3-year earnings per share growth (CAGR)
8.45%
10-year earnings per share growth (CAGR)
-0.71%
What the Analysts think about uniQure
Analyst ratings (Buy, Hold, Sell) for uniQure stock.
uniQure Financial Performance
Revenues and expenses
uniQure Earnings Performance
Company profitability
uniQure News
AllArticlesVideos
QURE CLASS ACTION NOTICE: Faruqi & Faruqi, LLP Reminds uniQure (QURE) Investors of Securities Class Action Deadline on April 13, 2026
Newsfile Corp·2 hours ago
QURE INVESTOR NOTICE: Faruqi & Faruqi, LLP Reminds uniQure (QURE) Investors of Securities Class Action Deadline on April 13, 2026
Newsfile Corp·3 days ago
ROSEN, A LEADING LAW FIRM, Encourages uniQure N.V. Investors to Secure Counsel Before Important Deadline in Securities Class Action - QURE
Newsfile Corp·4 days ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for uniQure stock?
uniQure (QURE) has a market cap of $1B as of March 24, 2026.
What is the P/E ratio for uniQure stock?
The price to earnings (P/E) ratio for uniQure (QURE) stock is 0 as of March 24, 2026.
Does uniQure stock pay dividends?
No, uniQure (QURE) stock does not pay dividends to its shareholders as of March 24, 2026.
When is the next uniQure dividend payment date?
uniQure (QURE) stock does not pay dividends to its shareholders.
What is the beta indicator for uniQure?
uniQure (QURE) has a beta rating of 0.77. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.